Data from a multicenter, double-blind, randomized trial, presented at the annual Digestive Disease Week meeting, showed that taking rabeprazole sodium (Medication Aciphex, Eisai/Janssen) and antibiotics for seven days was just as effective at treating Heliobacter pylori (H. pylori) bacteria as omeprazole (Prilosec tablet, AstraZeneca) and antibiotics for 10 days. H. pylori is believed to be [...]
The FDA has approved a New Drug Application (NDA) for omeprazole (Zegerid™ Powder for Oral Suspension, Santarus) 40 mg to reduce the risk of upper gastrointestinal bleeding in critically ill patients and for the short-term treatment of active benign gastric ulcers. An immediate-release oral proton-pump inhibitor (PPI), the powder is the only PPI approved for [...]
Wyeth has received the FDA’s Supplemental New Drug Application (SNDA) approval for room-temperature shipping and storage of tablet pantoprazole sodium for injection (Protonix® IV). This was the first proton-pump inhibitor (PPI) in the U.S. to be offered in both oral and intravenous (IV) formulations. As a result of this approval, IV panto-prazole can be stored [...]
ABILIFY (Aripiprazole) drug was developed by two companies: Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company. In 2004 Abilify medicine was approved in for treating schizophrenia disease and in 2008 it was ratified as medicine for bipolar disorder. It has been known today that the U.S. Food and Drug Administration (FDA) has accepted for filing [...]
Abilify drug was generally approved in 2004 for treating schizophrenia disease and this medicine was supposed to be used in treating bipolar disorder. Indeed, on April 8, 2008, the European Commission allowed Abilify medication (Aripiprazole) to be marketed for patients with Bipolar I Disorder. Such kind of disease as Bipolar I Disorder contains one or [...]
Abilify antipsychotic medicine was introduced in 2002 as the first and only dopamine partial agonist. It is generally prescribed for the treatment of schizophrenia disease and acute manic and mixed episodes associated with bipolar disorder. It has been known today that the US Food and Drug Administration (FDA) approved an oral solution formulation of Abilify [...]
Abilify (Aripiprazole) is considered to be an effective antipsychotic medication for treating schizophrenia disease and Bipolar I Disorder. The drug is developed by two partnered companies: Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company. They announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Abilify drug [...]
